{
    "body": "Is Vortioxetine effective for treatment of depression?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21154150", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21486038", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24284262", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24165478", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22171087", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22495621", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22963932", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24169027", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23252878", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24570588", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24311349", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24016840", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24257717", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23531115", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22978748", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23916504", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21767441", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23757185", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22572889", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22209361", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23903233", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22901346"
    ], 
    "ideal_answer": [
        "Yes, vortioxetine (Lu AA21004) is effective for treatment of major depressive disorder (MDD). Vortioxetine is approved for MDD in the USA. Vortioxetine has been also shown to be effective for treatment of generalized anxiety disorder."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.disease-ontology.org/api/metadata/DOID:1595", 
        "http://www.disease-ontology.org/api/metadata/DOID:1596", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003866", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003865", 
        "http://www.disease-ontology.org/api/metadata/DOID:1470", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003863", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016896", 
        "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812"
    ], 
    "type": "yesno", 
    "id": "53359338d6d3ac6a3400004f", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 400, 
            "text": "Vortioxetine is an orally administered small molecule developed by Lundbeck A/S for the once-daily treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD). Vortioxetine received its first global approval for MDD in the USA in September 2013 and regulatory approval for its use in this indication in the EU (where it has received a positive opinion) and Canada is awaited. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24311349", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1167, 
            "offsetInEndSection": 1280, 
            "text": "This article summarizes the milestones in the development of vortioxetine leading to this first approval for MDD.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24311349", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1559, 
            "offsetInEndSection": 1667, 
            "text": "Vortioxetine was efficacious and well tolerated in the treatment of patients with major depressive disorder.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24257717", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 863, 
            "offsetInEndSection": 1123, 
            "text": "On the primary efficacy endpoint, both vortioxetine doses were statistically significantly superior to placebo, with a mean difference to placebo (n=158) of -5.5 (vortioxetine 15 mg, P<0.0001, n=149) and -7.1 MADRS points (vortioxetine 20 mg, P<0.0001, n=151).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24257717", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1350, 
            "offsetInEndSection": 1595, 
            "text": "The change in the severity of depressive and anxiety symptoms was maintained throughout the study as reflected by a 24-item Hamilton Depression Scale total score of 8.2 at week 52 (from 17.6 at open-label baseline) in the observed case data set.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24169027", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 795, 
            "offsetInEndSection": 1006, 
            "text": "Vortioxetine is a multi-modal antidepressant that functions as a human 5-HT3A and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist, and inhibitor of the serotonin transporter. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24165478", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1049, 
            "offsetInEndSection": 1258, 
            "text": "Approval for the treatment of MDD was based on a clinical development programme that included six positive 6-8 week studies, including one study in elderly people, and one positive maintenance study in adults.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24165478", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1855, 
            "offsetInEndSection": 1920, 
            "text": "Vortioxetine represents another option for the treatment of MDD. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24165478", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1193, 
            "offsetInEndSection": 1503, 
            "text": "The multimodal compounds vortioxetine and vilazodone are examples of this approach with diverse mechanisms, and their different clinical effects will provide valuable insights into serotonergic modulation of glutamate transmission for the potential treatment of depression and associated cognitive dysfunction.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23903233", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1733, 
            "offsetInEndSection": 1897, 
            "text": "Two new antidepressant drugs, vilazodone (marketed in the USA) and vortioxetine (in development) incorporate partial 5-HT1A-R agonist properties with SERT blockade.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23757185", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 786, 
            "offsetInEndSection": 1388, 
            "text": "Novel drugs in development include those that combine multiple simultaneous pharmacologic mechanisms in addition to SERT inhibition within the same molecule, such as vilazodone (combining 5HT1A partial agonism with SERT inhibition), triple reuptake inhibitors (combining norepinephrine and dopamine reuptake inhibition with SERT inhibition), and vortioxetine, a multimodal antidepressant combining actions at the G protein receptor mode (5HT1A and 5HT1B partial agonism and 5HT7 antagonism), at the ion channel mode (5HT3 antagonism) as well as the neurotransmitter transporter mode (SERT inhibition). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23531115", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1847, 
            "offsetInEndSection": 2034, 
            "text": "In this study of adults with MDD treated for 8 weeks with vortioxetine 2.5\u2009mg or 5\u2009mg per day, reductions in depression symptoms were not statistically significant compared with placebo. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23252878", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1744, 
            "offsetInEndSection": 1934, 
            "text": "However, on the basis of these findings, vortioxetine (2.5, 5, 10\u2009mg/day) demonstrated a favourable safety and tolerability profile and maintained effectiveness over 12 months of treatment. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22978748", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1486, 
            "offsetInEndSection": 1636, 
            "text": "In this study of adults with MDD, 5 mg vortioxetine did not differ significantly from placebo in reducing depression symptoms after 6 wk of treatment.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22963932", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1688, 
            "offsetInEndSection": 1836, 
            "text": "After 8 weeks of treatment with Lu AA21004 10 mg, there was a significant reduction in HDRS-24 total score compared with placebo in adults with MDD.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22901346", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1382, 
            "offsetInEndSection": 1521, 
            "text": "In conclusion, Lu AA21004 was efficacious and well tolerated in the treatment of elderly patients with recurrent major depressive disorder.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22572889", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1151, 
            "offsetInEndSection": 1259, 
            "text": "Thus, Lu AA21004 was effective in preventing relapse of MDD and was well tolerated as maintenance treatment.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22495621", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1637, 
            "offsetInEndSection": 1785, 
            "text": " Findings on secondary outcome measures, using MMRM instead of LOCF, were supportive of likely efficacy for Lu AA21004 5mg and 10mg and duloxetine. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22209361", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1525, 
            "offsetInEndSection": 1646, 
            "text": "In this study, treatment with 5 mg and 10 mg Lu AA21004 for 6 wk was efficacious and well tolerated in patients with MDD.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21767441", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 700, 
            "offsetInEndSection": 827, 
            "text": "Results from phase II clinical trials have reported improvement in depression and anxiety symptoms after 6 weeks of treatment. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21154150", 
            "endSection": "abstract"
        }
    ]
}